#Business #WallStreet
GSK struck a deal to buy the rights to CureVac’s Covid-19 and flu vaccines for up to $1.56 billion, in a bid to regain ground lost to newcomers to the vaccine market during the pandemic.
WSJ.com: US Business
PAID
This is a business article located in the U.S. Business section of the Wall Street Journal. For the latest articles on U.S. business, current markets and other business related news follow our Twitter Page or bookmark this website.
